



Grand Brilliance

Group Holdings Limited

君百延集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock code: 8372

2022

THIRD QUARTERLY REPORT

CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “HONG KONG STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Hong Kong Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Hong Kong Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Hong Kong Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the “Directors”) of Grand Brilliance Group Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “We”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Hong Kong Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to the Group. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this report is accurate and complete in all material respects and not misleading and deceptive; (2) there are no other matters the omission of which would make any statement in this report misleading; and (3) all opinions expressed in this report have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

THIRD QUARTERLY RESULTS

The board of the Directors (the “Board”) of the Company is pleased to announce the unaudited condensed consolidated results of the Group for the nine months ended 31 December 2022, together with the comparative figures for the corresponding period in 2021, as follows:

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the three months and nine months ended 31 December 2022

	Notes	Three months ended 31 December		Nine months ended 31 December	
		2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)
Revenue	4	16,913	20,344	49,937	51,699
Cost of revenue		(8,285)	(10,308)	(24,060)	(24,455)
Gross profit		8,628	10,036	25,877	27,244
Other income		428	–	1,223	18
Other gains or losses		524	(83)	(24)	(208)
Distribution and selling expenses		(235)	(367)	(847)	(863)
Administrative and other operating expenses		(6,733)	(6,751)	(20,280)	(19,592)
Finance costs	5	(37)	(41)	(106)	(106)
Share of losses of an associate		(89)	–	(134)	–
Profit before income tax	6	2,486	2,794	5,709	6,493
Income tax expense	7	(510)	(686)	(1,187)	(1,334)
Profit and total comprehensive income for the period attributable to owners of the Company		1,976	2,108	4,522	5,159
Earnings per share attributable to owners of the Company		HK cent	HK cent	HK cent	HK cent
Basic and diluted earnings per share	9	0.25	0.26	0.56	0.64

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the nine months ended 31 December 2022

	Share capital HK\$'000	Share premium HK\$'000	Merger reserve HK\$'000	Share option reserve HK\$'000	Retained earnings HK\$'000	Total HK\$'000
At 1 April 2021 (audited)	8,000	52,499	1,500	1,006	30,047	93,052
Profit and total comprehensive income for the period	-	-	-	-	5,159	5,159
Recognition of equity-settled share-based payment	-	-	-	9	-	9
Dividend declared (Note 8)	-	-	-	-	(3,600)	(3,600)
At 31 December 2021 (unaudited)	8,000	52,499	1,500	1,015	31,606	94,620
At 1 April 2022 (audited)	8,000	52,499	1,500	1,015	30,495	93,509
Profit and total comprehensive income for the period	-	-	-	-	4,522	4,522
Dividend declared (Note 8)	-	-	-	-	(2,400)	(2,400)
At 31 December 2022 (unaudited)	8,000	52,499	1,500	1,015	32,617	95,631

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended 31 December 2022

1. GENERAL INFORMATION

The Company was incorporated in the Cayman Islands with limited liability under the Companies Law, Cap. 22 of the Cayman Islands on 5 July 2017. Its shares have been listed on GEM of the Hong Kong Stock Exchange on 29 March 2018 (the "Listing"). The address of the Company's registered office is situated at Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands. The principal place of business of the Company is situated at Units 2901-03 and 2905, 29/F, The Octagon, 6 Sha Tsui Road, Tsuen Wan, New Territories, Hong Kong.

The Company is an investment holding company and its subsidiaries are principally engaged in supplying medical devices and providing medical device solutions including market trend analysis, sourcing of medical devices, after-sale services, technical support and training services, medical devices leasing services and quality assurance.

The Company's parent is B&A Success Limited ("B&A Success"), a company incorporated in the British Virgin Islands. In the opinion of the Directors, B&A Success is also the ultimate parent of the Company.

The condensed consolidated financial statements are presented in Hong Kong dollars ("HK\$"), which is the same as the functional currency of the Group.

2. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with all applicable Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards and Interpretations (hereinafter collectively referred to as the “HKFRSs”) issued by the Hong Kong Institute of Certified Public Accountants, the disclosure requirements of the Hong Kong Companies Ordinance and the GEM Listing Rules.

The condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual financial statements for the year ended 31 March 2022.

The condensed consolidated financial statements have been prepared under the historical cost basis, except for certain financial instruments which are measured at fair values.

The accounting policies adopted in preparing the unaudited condensed consolidated results for the nine months ended 31 December 2022 are consistent with those adopted in the audited financial statements for the year ended 31 March 2022, except for a number of amendments to HKFRSs issued by the Hong Kong Institute of Certified Public Accountants that are effective for the current accounting period of the Group. The adoption of these new and revised HKFRSs has had no material effect on the Group’s results and financial position for the current or prior periods have been prepared or presented.

The Group has not early adopted any new and revised HKFRSs that have been issued but are not yet effective.

The condensed consolidated financial statements for the nine months ended 31 December 2022 have not been audited by the Company’s auditors, but have been reviewed by the audit committee of the Company (the “Audit Committee”).

3. SEGMENT INFORMATION

(a) Operating segment information

The Group determines its operating segments based on the reports reviewed by the chief operating decision-maker, i.e. Directors of the Company who are used to make strategic decisions.

During the reporting periods, the Directors assess the operating performance and allocate the resources of the Group as a whole as the Group is primarily engaged in supplying medical devices and providing medical device solutions including market trend analysis, sourcing of medical devices, after-sale services, technical support and training services, medical devices leasing services and quality assurance. Therefore the Group has only one operating segment that qualifies as reportable segment under HKFRS 8 Operating Segment.

(b) Geographical segment information

The Company is an investment holding company and the principal place of the Group's operations is in Hong Kong. Accordingly, management determines that the Group is domiciled in Hong Kong. All of the Group's revenue are derived from and most of the Group's non-current assets are located in Hong Kong. Accordingly, no separate segmental analysis is presented.

(c) Disaggregation of revenue from contracts with customers

	Three months ended 31 December		Nine months ended 31 December	
	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)
Timing of revenue recognition				
Over time	622	275	1,546	1,103
At a point in time	16,252	20,030	48,274	50,445
	16,874	20,305	49,820	51,548

(d) Information about major customers

For the nine months ended 31 December 2022, no revenue from single customer amounted for 10% or above of the total revenue of the Group.

For the nine months ended 31 December 2021, revenue from one customer amounted to HK\$6,498,000 which represented more than 10% of the total revenue of the Group.

4. REVENUE

The Group is principally engaged in supplying medical devices and providing medical device solutions including market trend analysis, sourcing of medical devices, after-sale services, technical support and training services, medical devices leasing services and quality assurance. Revenue derived from the principal activities comprises the following:

	Three months ended 31 December		Nine months ended 31 December	
	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)
Revenue from Contracts with customer: Sales of medical devices and products				
Medical consumables	13,100	13,174	38,990	36,653
Medical equipment	2,614	5,860	8,037	11,832
Medical instruments	538	996	1,247	1,960
	16,252	20,030	48,274	50,445
Rendering of maintenance services	622	275	1,546	1,103
	16,874	20,305	49,820	51,548
Revenue from other source: Rental income from leasing medical devices	39	39	117	151
	16,913	20,344	49,937	51,699

5. FINANCE COSTS

	Three months ended 31 December		Nine months ended 31 December	
	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)
Interest on lease liabilities	37	41	106	106

6. PROFIT BEFORE INCOME TAX

Profit before income tax is arrived at after charging/(crediting):

	Three months ended 31 December		Nine months ended 31 December	
	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)
Cost of inventories recognised as expense [#]				
— Carrying amount of inventories consumed	7,195	9,739	21,816	23,190
— (Reversal of)/allowance for inventories	(51)	72	(65)	(5)
— Write-off of inventories	652	—	652	—
	7,796	9,811	22,403	23,185
Change in fair value of financial assets measured at fair value through profits or loss	(141)	26	42	11
Depreciation of property, plant and equipment*	88	117	304	498
Depreciation of right-of-use assets*	1,001	973	2,978	2,663
Employee costs (including directors' emoluments)				
— Salaries, allowances and other benefits	3,840	4,064	11,645	11,652
— Contributions to defined contribution retirement plan ^{<}	131	131	383	391
— Equity-settled share-based payment expenses	—	—	—	9
	3,971	4,195	12,028	12,052
Bank interest income	(194)	—	(194)	(11)
Exchange difference, net	(382)	35	84	78
Research and development expenditure [^] (Reversal)/provision of loss allowance for trade receivables	478	828	1,591	1,197
	(2)	22	(103)	40

[#] Included in cost of revenue

^{*} Included in administrative and other operating expenses

[^] Included in research and development expenditure are staff costs amounted to approximately HK\$1,579,000 for the nine months ended 31 December 2022 (nine months ended 31 December 2021: approximately HK\$1,150,000) which have been included in the employee costs above.

[<] For the nine months ended 31 December 2022, no forfeited contribution in respect of the defined contribution retirement plans were utilised by the Group to reduce the contribution payable to the plans (nine months ended 31 December 2021: nil). As at 31 December 2022, no forfeited contribution under these plans is available to reduce future contribution (nine months ended 31 December 2021: nil).

7. INCOME TAX EXPENSE

The amount of income tax expense in the condensed consolidated statement of comprehensive income represents:

	Three months ended 31 December		Nine months ended 31 December	
	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)
Current tax for the period				
— Hong Kong Profits Tax	524	712	1,214	1,317
Over-provision in respect of prior years	—	(10)	—	(10)
Deferred tax	524 (14)	702 (16)	1,214 (27)	1,307 27
	510	686	1,187	1,334

The Group has no income subject to taxation in the Cayman Islands, the British Virgin Islands and United Kingdom. The Company and its Hong Kong incorporated subsidiaries are subject to Hong Kong Profits Tax, which is calculated at tax rate of 16.5% on the estimated assessable profits arising in Hong Kong during the period, except for one subsidiary of the Company which is a qualifying entity under the two-tiered profits tax rates regime. The first HK\$2,000,000 of assessable profits of this subsidiary are taxed at 8.25% and the remaining assessable profits are taxed at 16.5%.

8. DIVIDENDS

The Board resolved not to declare the payment of an interim dividend for the nine months ended 31 December 2022 (nine months ended 31 December 2021: Nil).

	Three months ended 31 December		Nine months ended 31 December	
	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)
Interim dividend for the year ended 31 March 2022 of HK0.3 cent per share (2021: HK0.45 cent per share)	—	—	2,400	3,600

Note:

An interim dividend of HK0.3 cent per ordinary share for the year ended 31 March 2022 was declared by the Board, which was paid on Monday, 15 August 2022 to the shareholders of the Company whose names appear on the register of members on Friday, 8 July 2022.

9. EARNINGS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY

The calculation of basic and diluted earnings per share is based on the following data:

	Three months ended 31 December		Nine months ended 31 December	
	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)	2021 HK\$'000 (Unaudited)
Earnings				
Profit for the period attributable to owners of the Company	1,976	2,108	4,522	5,159
	'000	'000	'000	'000
Weighted average number of ordinary shares in issue				
Weighted average number of ordinary shares for the purpose of calculating basic and diluted earnings per share	800,000	800,000	800,000	800,000

For the purpose of calculating diluted earnings per share for the nine months ended 31 December 2022 and 2021, no adjustment has been made as the exercise of the outstanding share options has an antidilutive effect on the basic earnings per share.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

We are an established medical device distributor and one-stop medical device solutions provider with over 20 years of experience in the medical device market in Hong Kong.

For the nine months ended 31 December 2022, the Group continued to implement our business strategy to solidify our position as a major medical device distributor in Hong Kong. We have established an associate company which will facilitate and bring about the Group's future business development in developing and establishing autonomous mobile robot solutions in the healthcare industries in order to support and sustain the growth of our business and expand our business. The Group aims to achieve its business growth through diversifying the product portfolio and enhance our research and development ability.

During the period under review, the COVID-19 pandemic continues to affect the Hong Kong's economy. The Group will further expand the product portfolio and enhance the customer services with a view to upgrade our one-stop medical device solutions services.

Looking ahead, while China and Hong Kong have lifted Covid-19 restrictions, we continue to be optimistic on the outlook of the medical and healthcare industry, attributable to the increase of aging population and rising healthcare awareness of the public in Hong Kong together with our automation solution to eliminate the medical manpower shortage crisis in Hong Kong. The Group is looking for suitable investment opportunities to diversify business and bring better investment return to the shareholders of the Company.

FINANCIAL REVIEW

Revenue

The Group's revenue decreased by approximately 3.4%, from approximately HK\$51.7 million for the nine months ended 31 December 2021 to approximately HK\$49.9 million for the nine months ended 31 December 2022. The decrease was primarily attributable to the decrease in revenue generated from medical equipment.

Gross profit and gross profit margin

The Group recorded gross profit of approximately HK\$25.9 million for the nine months ended 31 December 2022, representing a decrease by approximately HK\$1.3 million or 5.0%, as compared to approximately HK\$27.2 million for the nine months ended 31 December 2021.

Gross profit margin decreased from approximately 52.7% for the nine months ended 31 December 2021 to approximately 51.8% for the nine months ended 31 December 2022. The decrease in gross profit margin was mainly due to the fluctuations of overseas transportation costs.

Administrative and other operating expenses

Administrative and other operating expenses mainly included auditor's remuneration, advertising and marketing expenses, depreciation, Directors' remuneration, legal and professional fee, rent, rates and management fee for office and warehouses, staff costs, travelling and entertainment expenses and other miscellaneous expenses.

Administrative and other operating expenses for the nine months ended 31 December 2022 amounted to approximately HK\$20.3 million, representing an increase by approximately HK\$0.7 million or 3.5%, as compared to approximately HK\$19.6 million for the nine months ended 31 December 2021. The increase was primarily attributable to the increase of rents, rates and management fees of the Group for the nine months ended 31 December 2022.

Income tax expenses

Income tax expenses for the nine months ended 31 December 2022 amounted to approximately HK\$1.2 million (nine months ended 31 December 2021: approximately HK\$1.3 million).

Profit for the period

The Group's profit decreased by approximately HK\$0.7 million from approximately HK\$5.2 million for the nine months ended 31 December 2021 to approximately HK\$4.5 million for the nine months ended 31 December 2022. The decrease was primarily attributable to increase of administrative and other operating expenses during the period.

DIVIDEND

The Board resolved not to declare the payment of an interim dividend for the nine months ended 31 December 2022 (nine months ended 31 December 2021: Nil).

DIRECTORS' AND CHIEF EXECUTIVE'S INTEREST AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES OR DEBENTURES OF THE COMPANY OR ANY ASSOCIATED CORPORATION

As at 31 December 2022, the interests and short positions of the Directors and chief executive of the Company in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) which shall have to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO) or which shall be required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein or which shall be required to notify the Company and the Hong Kong Stock Exchange pursuant to Rule 5.46 to Rule 5.67 of the GEM Listing Rules, were as follows:

Long position in the shares and underlying shares in the Company and shares in associated corporations

Name of Director/ chief executive	Name of Group member/associated corporation	Nature of Interest	Number of shares	Number of underlying shares	Aggregate Interest	Approximate percentage of shareholding
Ms. Wong Bik Kwan Bikie ("Ms. Wong") (Note 1)	The Company	Interest in a controlled corporation	568,028,001	-		
		Beneficial owner	-	7,980,000		
			568,028,001	7,980,000	576,008,001	72.00%
	B&A Success	Beneficial owner	100 shares of US\$1.00 each	-	-	100%
Dr. Miu Yin Shun Andrew ("Dr. Miu") (Note 2)	The Company	Interest of spouse	568,028,001	7,980,000	576,008,001	72.00%
Mr. Chiu Man Wai ("Mr. Chiu") (Note 3)	The Company	Interest in a controlled corporation	9,620,000	-	9,620,000	1.20%
	Infinite Crystal Limited	Beneficial owner	900 shares of US\$1.00 each	-	-	100%
Mr. Chow Ming Po Aaron	The Company	Beneficial owner	7,810,000	-	7,810,000	0.98%

Notes:

- The shares are registered in the name of B&A Success, the entire issued share capital of which is legally and beneficially owned by Ms. Wong. Under the SFO, Ms. Wong is deemed to be interested in the same number of shares held by B&A Success.
- Dr. Miu is the spouse of Ms. Wong. Under the SFO, Dr. Miu is deemed to be interested in the same number of shares deemed to be held by Ms. Wong.
- The shares are registered in the name of Infinite Crystal Limited, the entire issued share capital of which is legally and beneficially owned by Mr. Chiu. Under the SFO, Mr. Chiu is deemed to be interested in the same number of shares held by Infinite Crystal Limited.

Save as disclosed above, as at 31 December 2022, none of the Directors and chief executive of the Company had any interests or short positions in any shares, underlying shares and debenture of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which would have to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or which were required to be notified to the Company and the Hong Kong Stock Exchange, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules.

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS AND SHORT POSITIONS IN SHARES OR UNDERLYING SHARES OF THE COMPANY

As at 31 December 2022, so far as the Directors are aware, other than the Directors or chief executive of the Company whose interests are disclosed under the paragraph headed "Directors' and chief executive's interest and short positions in shares, underlying shares or debentures of the Company or any associated corporation" above, the following persons had an interest or short position in the shares or underlying shares of the Company which shall be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or, directly or indirectly, were interested in 5.0% or more of the issued voting shares of any member of the Group:

Long position in the shares

Name of shareholders	Nature of Interest	Total number of shares	Approximate percentage of shareholding
B&A Success	Beneficial owner	568,028,001	71.00%

Saved as disclosed above and so far as is known to the Directors, the Directors were not aware of any other persons other than the Directors or chief executive of the Company who held an interest or short positions in the shares and underlying shares of the Company as at 31 December 2022 which required to be recorded pursuant to section 336 of the SFO.

SHARE OPTION SCHEME

The Company has adopted a share option scheme (“Share Option Scheme”) on 1 March 2018 to enable the Company to grant options to selected participants as incentives or rewards for their contribution to the Group and continuing efforts to promote the interest of the Group. The terms of the Share Option Scheme are in accordance with Chapter 23 of the GEM Listing Rules.

Details of Share Options and their movements during the nine months ended 31 December 2022 are as follows:

	Date of Grant	Exercise price per Share HK\$	Number of Shares issuable under the options				Exercise period	
			as at 01/04/2022	granted during the period	exercised during the period	lapsed during the period		as at 31/12/2022
Director								
Ms. Wong	18/04/2019	0.12	7,980,000	-	-	-	7,980,000	Note 1
Employees of the Group								
In aggregate	18/04/2019	0.12	13,480,000	-	-	-	13,480,000	Note 1
			21,460,000	-	-	-	21,460,000	

Notes:

- up to 40% of the Share Options are exercisable on or after 18 April 2019;
 - up to 70% of the Share Options are exercisable on or after 18 April 2020;
 - all the remaining Share Options are exercisable on or after 18 April 2021;

and in each case, not later than 17 April 2024.
- The closing price of the shares as stated in the Stock Exchange’s daily quotations sheet immediately before the date on which the share options are granted (i.e. 17 April 2019) was HK\$0.12.

Save as disclosed above, no options were granted, exercised, forfeited, cancelled or lapsed during the nine months ended 31 December 2022.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities during the nine months ended 31 December 2022.

DIRECTORS' SECURITIES TRADING TRANSACTIONS

The Group has adopted a code of conduct set out in the "required standard of dealings" in Rules 5.48 to 5.67 of the GEM Listing Rules. Having made specific enquiry of all Directors, all Directors have confirmed that they have been complying with the required standard of dealings and the related code of conduct regarding directors' securities transactions during the nine months ended 31 December 2022.

As far as the Group is aware, the Directors and employees of the Group have not breached the required standard of dealings and the code of conduct.

DIRECTORS' INTEREST IN COMPETING BUSINESS

None of the Directors and directors of the Company's subsidiaries, or any of their respective associates, as defined in the GEM Listing Rules, had interest in any business that competes or may compete, either directly or indirectly, with the businesses of the Group or has any other conflict of interests with the Group (other than being a director of the Company and/or its subsidiaries and their respective associates) during the nine months ended 31 December 2022.

CORPORATE GOVERNANCE PRACTICE

The Group has adopted the code provisions of the Corporate Governance Code (the "Code") as set out in Appendix 15 to the GEM Listing Rules. During the nine months ended 31 December 2022, the Group has complied with all the code provisions of the Code, except for the deviation stipulated below.

CHAIRMAN AND CHIEF EXECUTIVE OFFICER

According to the code provision C.2.1 of the Code, the roles of the chairman and chief executive should be separate and should not be performed by the same individual.

For the nine months ended 31 December 2022, the roles of chairman of the Board were performed by the chief executive officer, Ms. Wong. As the chairman of the Board, Ms. Wong is responsible for the formulating, planning and directing the Group's overall strategy and always seeks for Board approval for any significant decisions and transactions.

Although Ms. Wong performs both roles, the Board has conducted an assessment and believed that the independence, effectiveness and functionality of the Board and the Group's operations has been and will be highly maintained together with independent check and balance measures in place as the Board has sufficient number of Directors who have diversified background and expertise.

AUDIT COMMITTEE

The Company established the Audit Committee on 1 March 2018 with written terms of reference in compliance with the GEM Listing Rules which are available on the websites of the GEM and the Company. The Audit Committee currently consists of two independent non-executive Directors, namely Mr. Wong Lung Wo James and Mr. Chow Ming Po Aaron, and one non-executive Director, namely Dr. Miu Yin Shun Andrew. Mr. Wong Lung Wo James has the appropriate accounting and financial related management expertise and serves as the chairman of the Audit Committee.

The Audit Committee of the Company has reviewed the unaudited condensed consolidated financial statements of the Group for the nine months ended 31 December 2022, and is of the opinion that such statements complied with the applicable accounting standards, the requirements under the GEM Listing Rules, and that adequate disclosures have been made.

By order of the Board
Grand Brilliance Group Holdings Limited
Wong Bik Kwan Bikie
Chairman and Chief Executive Officer

Hong Kong, 10 February 2023

As at the date of this report, the executive Director is Ms. Wong Bik Kwan Bikie; the non-executive Directors are Dr. Miu Yin Shun Andrew and Mr. Chiu Man Wai; and the independent non-executive Directors are Mr. Ng Leung Sing SBS, JP, Mr. Wong Lung Wo James and Mr. Chow Ming Po Aaron.